Minor
ICP-332 · Prurigo Nodularis
Trial sites expanded: 34 → 43 locations
Beijing InnoCare Pharma Tech Co., Ltd.Phase 2 NCT07236099 Registry history of NCT07236099 on ClinicalTrials.gov (opens the registry)
Updated
26 active trials 20 recruiting 8 Phase 3 10 disease areas 1 changes in 30 days
1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Trial sites expanded: 34 → 43 locations
Beijing InnoCare Pharma Tech Co., Ltd.Phase 2 NCT07236099 Registry history of NCT07236099 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 5 | |
| Phase 1/2 | 6 | |
| Phase 2 | 7 | |
| Phase 2/3 | 3 | |
| Phase 3 | 5 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06842199 | Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque… | Plaque Psoriasis Patients | Recruiting | 2026-02-09 |
| NCT06082102 | Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined… | Relapsed/Refractory Marginal Zone Lymphoma | Recruiting | 2025-09-15 |
| NCT06775860 | ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | Recruiting | 2025-09-08 |
| NCT06521255 | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With… | DLBCL | Recruiting | 2024-07-25 |
| NCT07784101 | A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib… | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Not Yet Recruiting | 2026-08-25 |
| Phase 2/3 | ||||
| NCT07378527 | Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous… | Chronic Spontaneous Urticaria (CSU) | Recruiting | 2026-04-21 |
| NCT06378138 | ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic… | Hematologic Malignancies | Recruiting | 2025-11-21 |
| NCT07047612 | ICP-332 in Subjects With Non-segmental Vitiligo | Non Segmental Vitiligo | Recruiting | 2025-08-07 |
| Phase 2 | ||||
| NCT07236099 | Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis | Prurigo Nodularis (PN) | Recruiting | 2026-09-14 |
| NCT07082686 | A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or… | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Recruiting | 2026-07-23 |
| NCT07440537 | Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus… | Cutaneous Lupus Erythematosus (CLE) | Recruiting | 2026-06-08 |
| NCT07251998 | Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe… | Plaque Psoriasis | Recruiting | 2025-12-31 |
| NCT05678270 | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic… | Intrahepatic Cholangiocarcinoma (ICC) | Recruiting | 2024-02-07 |
| NCT05552937 | Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients… | DLBCL | Recruiting | 2022-09-23 |
| NCT07727486 | A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary… | Primary Sjögren's Syndrome | Not Yet Recruiting | 2026-07-27 |
| Phase 1/2 | ||||
| NCT07617493 | Evaluation of ICP-B208 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | 2026-07-10 |
| NCT05745623 | Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System… | Advanced Solid Tumors Harboring NTRK Fusion | Recruiting | 2025-09-11 |
| NCT04685226 | A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors | Solid Tumors | Recruiting | 2025-09-02 |
| NCT04014205 | A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell… | Part 1：r/r B-cell Malignancies | Active, Not Recruiting | 2026-06-08 |
| NCT06845241 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or… | Relapsed or Refractory Non-Hodgkin Lymphoma | Not Yet Recruiting | 2025-02-25 |
| NCT05210868 | A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's… | Hematoma | Active, Not Recruiting | 2022-01-27 |
| Phase 1 | ||||
| NCT06656494 | ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid… | Acute Myelogenous Leukemia | Recruiting | 2026-08-18 |
| NCT07535099 | Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in… | Health Services Research | Recruiting | 2026-06-18 |
| NCT05728658 | The Study of ICP-248 in Patients With Mature B-cell Malignancies | Hematological Malignancies | Recruiting | 2025-09-08 |
| NCT05690581 | Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced… | Advanced Solid Tumors and Hematologic Malignancies | Recruiting | 2024-12-27 |
DLBCL (2) · Mantle Cell Lymphoma (2) · Psoriasis (2) · Acute Myeloid Leukemia (AML) (1) · Atopic Dermatitis (1) · Cholangiocarcinoma (1) · Leukemia (1) · Lupus (SLE) (1) · Myelodysplastic Syndromes (MDS) (1) · Non-Hodgkin Lymphoma (1)